Amundi
LGND icon

Amundi’s Ligand Pharmaceuticals LGND Stock Holding History

Amundi’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
3,601
+46
+1% +$10.8K ﹤0.01% 1326
2026
Q1 		$710K Buy
3,555
+522
+17% +$103K ﹤0.01% 1407
2025
Q4 		$573K Sell
3,033
-323
-10% -$62.1K ﹤0.01% 1424
2025
Q3 		$613K Buy
3,356
+229
+7% +$34K ﹤0.01% 1274
2025
Q2 		$355K Sell
3,127
-4,500
-59% -$481K ﹤0.01% 1458
2025
Q1 		$786K Sell
7,627
-1,921
-20% -$217K ﹤0.01% 1387
2024
Q4 		$1.06M Buy
9,548
+6,332
+197% +$716K ﹤0.01% 1392
2024
Q3 		$331K Buy
3,216
+582
+22% +$58.6K ﹤0.01% 1527
2024
Q2 		$218K Sell
2,634
-240
-8% -$19.1K ﹤0.01% 1564
2024
Q1 		$208K Buy
2,874
+709
+33% +$52.3K ﹤0.01% 1628
2023
Q4 		$159K Buy
2,165
+141
+7% +$8.32K ﹤0.01% 1684
2023
Q3 		$111K Hold
2,024
– – ﹤0.01% 1735
2023
Q2 		$147K Sell
2,024
-163
-7% -$12.2K ﹤0.01% 1682
2023
Q1 		$156K Buy
+2,187
New +$155K ﹤0.01% 1636

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's LGND Position: Q2 2026 in Review

Amundi increased its Ligand Pharmaceuticals (LGND) stake by 1.3% in Q2 2026, buying an estimated $10.8K and bringing the position to 3,601 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1326.

Amundi first reported a position in LGND in Q1 2023 and has held it in 14 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Amundi held 3,601 shares of Ligand Pharmaceuticals worth $1.14M as of Q2 2026.
  • Amundi bought 46 Ligand Pharmaceuticals shares in Q2 2026, an estimated $10.8K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1326 holding.
  • Amundi first reported a position in Ligand Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.